I'll research UHS before writing the preview. Let me start by gathering recent earnings materials, filings, and news.I'll read the most recent earnings materials and gather more context.Let me gather the 2026 guidance details (set on the Q4 call), recent news, and stock price context.The stock has fallen sharply (from ~$235 in Feb to ~$155 now). Let me get the year-ago Q2 comparison and recent news/context on the Talkspace close and sector dynamics.I have strong data. Let me quickly check the July 21 credit facility 8-K for the Talkspace context, and pull a bit of macro/sector news backdrop.I have what I need. Let me run a couple of quick calculations to frame the setup precisely before writing.I now have everything needed to write the preview.

Universal Health Services (UHS) — Q2 2026 Earnings Preview

Reporting after market close Monday, July 27, 2026 | Call Tuesday, July 28

The setup in one line

This is arguably the most important print of UHS's year: management said in April it would revisit full-year guidance in conjunction with Q2 earnings, so the update to the 2026 outlook — not the Q2 number itself — is the main event. It comes with the stock deeply out of favor (down ~34% from its February peak and ~29% YTD), a pending Talkspace acquisition apparently near closing, and a heavy stack of known 2026 headwinds (ACA exchange erosion, California behavioral staffing rules, and a tough Medicaid supplemental-payment comparison) that begin to bite hardest in the back half.

1. Price action & sentiment: a broken stock going in

UHS shares have de-rated sharply in 2026: - ~$220 to start the year → peaked ~$235 in mid-February → $155.78 on July 24. - The Q1 print (reported April 27) triggered a ~9.5% one-day drop (from $179.51 to $162.54), and the stock kept sliding to lows near $142 in early June before a modest recovery.

The de-rating reflects sector-wide worry more than company-specific misses: the July 4, 2025 reconciliation law (Medicaid work requirements, provider-fee/DPP limits, ACA subsidy expiration) and the mechanics of exchange disenrollment have compressed hospital multiples. The upshot for the setup: expectations and positioning are low, so the guidance revision and management's commentary on 2027 policy exposure will likely drive the reaction more than the Q2 EPS beat/miss.

2. What Q2 actually needs to show (the math)

Year-ago comp is tough. Q2 2025 delivered adjusted EPS of $5.35, revenue of $4.284B, and adjusted EBITDA net of NCI of $642.9M — but that quarter included roughly $101M of net incremental Medicaid supplemental payments (≈$58M from the newly approved Tennessee DPP covering July 2024–June 2025, plus ~$43M of other/retroactive amounts), partly offset by a ~$25M start-up loss at the Cedar Hill (D.C.) de novo. Lapping that one-time DPP benefit is a real headwind to reported year-over-year growth this quarter.
Full-year guidance implies a back-half ramp. 2026 guidance (set Feb 25, reaffirmed April 28): revenue $18.4–18.8B (+6–8%), adjusted EBITDA net of NCI $2.64–2.79B (+2–8%), adjusted EPS $22.64–24.52 (+4–13%), built on ~5% core consolidated growth. With Q1 adjusted EPS at $5.62, the remaining three quarters need to average roughly $5.7 (low) to $6.3 (high) — i.e., the year is explicitly back-end loaded, which raises the bar for Q2 commentary to confirm the H2 acceleration is on track.
Buybacks are a tailwind. Diluted share count is already ~5% lower year-over-year (61.7M in Q1'26 vs 65.0M in Q2'25), cushioning EPS even where EBITDA growth is muted.

Watch: whether management raises, trims, or reaffirms the range. A Florida DPP approval (below) could support a raise; a faster-than-expected exchange fall-off or California ramp costs could pressure it.

3. The three "unique to 2026" swing factors

a) ACA exchange (HICS) erosion — the biggest wildcard. Guidance embeds a ~$75M full-year pre-tax hit, assuming exchange volumes fall 25–30% with most lost members shifting to self-pay/uninsured, concentrated in acute care (exchanges were ~6% of acute adjusted admissions / <5% of acute revenue in 2025). Q1 impact was only ~$15M (reported exchange admissions down ~5%, but reserved as if down low-double-digits), and management said the drag "will steepen as the year progresses." Q2 is the first quarter where the ramp should become visible — pace of erosion, payer-mix shift, and bad-debt/uncompensated-care trends are the key tells for both 2026 and the 2027 exit rate.

b) California behavioral staffing ratios (effective June 1). A ~$35M 2026 pre-tax headwind (~$30M ongoing thereafter) from shifting to a more RN-heavy staffing mix, including recruiting/training costs and possible short-term census disruption. Q2 captures only ~one month of the rule, so watch for early read on cost ramp and any volume disruption in the California facilities, plus any progress toward Medi-Cal/commercial reimbursement offsets.

c) Medicaid supplemental payments (DPP). 2026 assumes $1.36B net supplemental benefit (+~$23M YoY, including a new Nevada program). Two catalysts: - Florida — a pending 2025 program management repeatedly flags as "likely to be approved," worth ~$45–50M (potentially higher), not yet in guidance. Approval in/around Q2 would be recognized in-period and could support a guidance raise. - California — a possible expanded program viewed as far less certain; nothing is baked in.

4. Operating trends to monitor

Acute care volumes / normalization. Q1 same-facility adjusted admissions were flat (hurt ~200 bps by weak flu/respiratory and winter weather; ~$5–7M direct weather hit, largely a D.C. burst-pipe bed closure). Management called March a "cleaner" month and expects volumes to improve. With the weather/flu distortions gone, Q2 is the cleaner read on underlying acute demand — watch surgical volumes, ED trends, and the higher-acuity service lines (cardiology, orthopedics, neurology) that lifted Q1 pricing (+6.3% revenue/adjusted admission). Also watch the Las Vegas/Nevada market recovery (tourism-sensitive; management expects a 2026 uptick tied to convention bookings).

Behavioral volume & wage trajectory. The bull case rests on behavioral inflecting toward the 2–3% patient-day growth target as 2025's staffing investments pay off. Q1 same-facility adjusted patient days were +1.6% (weather-dampened ~40–50 bps); revenue/day +5.8%. Also watch wage moderation (behavioral SWB/day was ~6% in Q1 vs 7–8% in 2025, expected to ease further) and continued turnover improvement. Note pricing is guided to moderate to 2–3% in 2026 as elevated contract rates anniversary.

Cost control & margins. Acute margins have been the standout (contract labor ~2.3% of segment revenue; disciplined supply spend). Management flagged professional fees (hospital-based physicians, radiology) rising at high-single-digit rates as the category to watch.

De novo / capacity ramp. Several projects are the engine of the H2 ramp: the 156-bed Palm Beach Gardens (FL) de novo (opened May; expected to run an operating loss in year one), 178 beds of tower/replacement capacity in FL/CA/Las Vegas coming online in Q2 (should ramp quickly in existing markets), and Cedar Hill (D.C.) improvement (now characterized as more back-half-weighted). The ~$50M net Cedar Hill/Palm Beach wash is a guidance assumption worth tracking.

5. Talkspace: is it closing, and what does it do to numbers?

On July 20, UHS added a new $700M delayed-draw Tranche A term loan (drawable through Sept 30, 2026; 364-day, non-amortizing, to be prepaid upon a debt/equity issuance). This is on top of the $400M delayed-draw loan set up in April earmarked for the Talkspace close and a $900M facility upsize. The financing cadence strongly suggests the deal is near closing — expect a timing/close update and likely more detail on integration and accretion.
Management frames Talkspace as accretive within the first 12 months, "increasingly accretive thereafter," with an effective EBITDA multiple in the single digits by year 3, and as the anchor of an end-to-end behavioral continuum (virtual IOPs, step-down, 6,000 clinicians across 50 states). Watch for any initial 2026 P&L contribution/dilution framing once closed, and whether it changes the buyback pace.

6. Capital allocation & balance sheet

Leverage is low (~1.7–1.8x debt/EBITDA), giving flexibility even with Talkspace (management said it moves leverage from just under 2x to a little over 2x). Preferred range is 2–3x.
Buybacks: FY target ~$800–900M "at a minimum"; only $127M repurchased in Q1, so repurchase pace is a swing factor for EPS and a signal of confidence. Watch whether they stay active around the Talkspace close (they said they would). ~$1.3B authorization remained at Q1.
Cash flow: rule of thumb is OCF ≈ 75–80% of operating income less NCI; Q1 OCF was $402M.

7. Policy / 2027 overhang

Even with 2026 largely mapped, investors will press on 2027+ exposure: Medicaid work requirements (management, like peers, has declined to quantify — expects disenrolled members to be lighter utilizers), provider-fee/DPP limits scheduled to begin phasing in 2028, and the permanent loss of enhanced ACA subsidies. Management's strategic hedge — growing higher-margin, more-commercial outpatient behavioral (1,000 Branches + Talkspace) — is the counter-narrative to watch. Note also emerging bipartisan price-transparency legislation as a longer-term industry theme.

Bottom line — what will move the stock

The guidance revision (raise/hold/cut) and the credibility of the implied H2 ramp.
Exchange (HICS) erosion pace and bad-debt trends — the single most-watched data point for 2026 and the 2027 setup.
Behavioral volume inflection toward 2–3% plus continued wage moderation.
Florida DPP approval (potential upside not in guidance) and California staffing-rule ramp costs.
Talkspace close timing / accretion and buyback cadence.

With the stock down roughly a third from its highs and positioning defensive, a clean acute volume read, confirmation of the behavioral ramp, and a maintained-or-raised outlook could be enough for a relief move; conversely, any sign the exchange headwind is running ahead of plan or that the back-half ramp is slipping would validate the bearish de-rating.

Note: Figures above are drawn from UHS's Q1 2026 and Q4 2025 earnings materials, the Q2 2025 release (year-ago comp), and the July 20, 2026 8-K. I did not have access to current sell-side consensus estimates, so Q2 expectations are framed against guidance and the year-ago base rather than a specific Street number.